Open AccessJournal Article
Triple-Combination Treatment with Olmesartan Medoxomil/ Amlodipine/ Hydrochlorothiazide in Hispanic/Latino Patients with Hypertension: The TRINITY Study
Andrew J. Lewin,Dean J. Kereiakes,Steven G. Chrysant,Joseph L. Izzo,Suzanne Oparil,James Lee,Victor Fernandez,Michael Melino +7 more
Reads0
Chats0
TLDR
The efficacy of triple-drug therapy in achieving BP goal was sustained long-term (40-week open-label extension period) in Hispanic/Latino and non-Hispanic/ Latino participants.Abstract:
Objective(s): Evaluate efficacy/safety of olmesartan medoxomil (OM)/amlodipine (AML)/ hydrochlorothiazide (HCTZ) in Hispanic/Latino adults with hypertension. Design: Randomized, double-blind, 12-week, parallel-group study followed by a 40-week open-label extension phase. Setting: Clinical sites (317) in the United States and Puerto Rico. Patients or Participants: Individuals ≥18 years of age with mean seated blood pressure (BP) ≥140/100 or ≥160/90 mm Hg divided into Hispanic/Latino (369) and non-Hispanic/Latino (2122) subgroups. Interventions: Participants were randomized to OM 40/AML 10 mg, OM 40/HCTZ 25 mg, AML 10/HCTZ 25 mg, or OM 40/AML 10/HCTZ 25 mg during the double-blind phase. During the open-label extension, all participants received OM 40/AML 5/HCTZ 12.5 mg; participants not reaching BP goal within 2 weeks were randomly titrated to OM40/AML 10/HCTZ 12.5mg or OM 40/AML 5/HCTZ 25mg, then to OM40/AML 10/ HCTZ 25 mg after another 2 weeks. Main Outcome Measure: Change in mean seated diastolic BP (SeDBP) from baseline (double-blind phase). Results: Triple-drug therapy vs the dual therapies resulted in greater mean reduction in SeBP (Hispanic/Latino: 35.0/20.9 mm Hg vs 27.8– 30.9/15.3–17.7 mm Hg; non-Hispanic/Latino: 39.0/21.7 mm Hg vs 28.9–31.5/14.6–17.8 mm Hg) and enabled more participants to reach BP goal (Hispanic/Latino: 56.8% vs 40.6%–51.2%; non-Hispanic/Latino: 65.7% vs 33.8%–46.6%) irrespective of ethnicity. The efficacy of triple-drug therapy in achieving BP goal was sustained long-term(40-week open-label extension period) in Hispanic/Latino (63.3%) and non-Hispanic/ Latino (64.2%) participants. Triple-drug therapy was well tolerated in Hispanic/Latino and non- Hispanic/Latino participants. Conclusions: In this study, OM/AML/HCTZ was an effective treatment option in Hispanic/ Latino patients with hypertension. (Ethn Dis. 2014;24[1]:41–47)read more
Citations
More filters
Journal ArticleDOI
Renin-angiotensin system in the kidney: What is new?
TL;DR: New enzymes, alternative routes for Ang IIformation or even active Ang II-derived peptides have now been described acting on Ang II AT1 or AT2 receptors, or in receptors which have recently been cloned, such as Mas and AT4.
Journal ArticleDOI
From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America
M. Larissa Avilés-Santa,Uriyoán Colón-Ramos,Nangel M. Lindberg,Josiemer Mattei,Francisco J. Pasquel,Cynthia M. Pérez +5 more
TL;DR: This review will focus on the epidemiology, etiology and prevention of type 2 DM in populations of Latin American origin, and the representation of Hispanics/Latinos in pharmacological and non-pharmacological clinical trials has been suboptimal.
Journal ArticleDOI
Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform
Massimo Volpe,Giuliano Tocci,Alejandro de la Sierra,Reinhold Kreutz,Stéphane Laurent,Athanasios J. Manolis,Kostantinos Tsioufis +6 more
TL;DR: An update of the practical therapeutic platform for the treatment of hypertension is presented, which takes into account the results of the recently published studies and extends the applicability of the platform to common conditions that are often neglected or poorly considered in clinical practice guidelines.
Journal ArticleDOI
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload–induced Cardiac Hypertrophy and Remodeling in Male Mice
Yong Ye,Hui Gong,Xingxu Wang,Jian Wu,Shijun Wang,Jie Yuan,Peipei Yin,Guoliang Jiang,Yang Li,Zhiwen Ding,Weijing Zhang,Jingmin Zhou,Junbo Ge,Yunzeng Zou +13 more
TL;DR: Although pressure overload–induced cardiac remodeling and dysfunction, hypertrophic gene reprogramming, AT1-R and &bgr;1-AR expression, and ERK phosphorylation were significantly attenuated by QL alone, the attenuation was stronger in the combination treatment groups.
Journal ArticleDOI
Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta‐analysis
TL;DR: Nifedipineranked the highest and lacidipine ranked the lowest amongst DHPCCBs for developing peripheral edema when used for cardiovascular indications, and the effects of renin‐angiotensin system blockers on DHP CCBs network meta‐analysis were created to analyze the ranking of the reduction of peripheral edma.
References
More filters
Journal ArticleDOI
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: In those older than age 50, systolic blood pressure of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP, and hypertension will be controlled only if patients are motivated to stay on their treatment plan.
Journal ArticleDOI
Heart Disease and Stroke Statistics—2013 Update A Report From the American Heart Association
Alan S. Go,Dariush Mozaffarian,Véronique L. Roger,Emelia J. Benjamin,Jarett D. Berry,William B. Borden,Dawn M. Bravata,Shifan Dai,Earl S. Ford,Caroline S. Fox,Sheila Franco,Heather J. Fullerton,Cathleen Gillespie,Susan M. Hailpern,John A. Heit,Virginia J. Howard,Mark D. Huffman,Brett M. Kissela,Steven J. Kittner,Daniel T. Lackland,Judith H. Lichtman,Lynda D. Lisabeth,David J. Magid,Gregory M. Marcus,Ariane Marelli,David B. Matchar,Darren K. McGuire,Emile R. Mohler,Claudia S. Moy,Michael E. Mussolino,Graham Nichol,Nina P. Paynter,Pamela J. Schreiner,Paul D. Sorlie,Joel Stein,Tanya N. Turan,Salim S. Virani,Nathan D. Wong,Daniel Woo,Melanie B. Turner +39 more
TL;DR: Author(s): Go, Alan S; Mozaffarian, Dariush; Roger, Veronique L; Benjamin, Emelia J; Berry, Jarett D; Borden, William B; Bravata, Dawn M; Dai, Shifan; Ford, Earl S; Fox, Caroline S; Franco, Sheila; Fullerton, Heather J; Gillespie, Cathleen; Hailpern, Susan M; Heit, John A; Howard, Virginia J; Huff
Journal ArticleDOI
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
TL;DR: Fixed-dose combination decreases the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension for improving medication compliance which can translate into better clinical outcomes.
Journal ArticleDOI
Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. A Meta-Analysis
TL;DR: Compared with free-drug combinations, FDCs of antihypertensive agents are associated with a significant improvement in compliance and with nonsignificant beneficial trends in BP and adverse effects.
Journal ArticleDOI
Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals
Eni C. Okonofua,Kit N. Simpson,Ammar Jesri,Shakaib U. Rehman,Valerie Durkalski,Brent M. Egan +5 more
TL;DR: Therapeutic inertia (TI), defined as the providers’ failure to increase therapy when treatment goals are unmet, contributes to the high prevalence of uncontrolled hypertension, but the quantitative impact is unknown.